Skip to main content
SpringerLink
Log in

Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study

  • Urology - Original article
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

The effect of adjuvant radiation therapy on survival in sarcomatoid renal cell carcinoma (sRCC) with no evidence of distant metastasis remains unclear.

Methods

Subjects diagnosed with non-metastatic sRCC were identified using the Surveillance Epidemiology and End Results (SEER) (2004–2012) database and divided into groups based on their surgical treatment (ST): no surgery or radiation therapy (NSR); partial nephrectomy (PNE); radical nephrectomy with ureterectomy and bladder cuff resection (RNE + UE + BLAD); and radical nephrectomy (RNE). Certain radical nephrectomy cases also received adjuvant external-beam radiation therapy (RNE + RAD). The Kaplan–Meier method was used to estimate overall survival (OS). A multivariable competing risks regression analysis was used to calculate disease-specific survival (DSS) probability and to determine factors associated with cause-specific mortality (CSM).

Results

A total of 408 patients were included in this study. The 5-year OS and predicted DSS were significantly higher in the patients who underwent STs (i.e., PNE, RNE + UE + BLAD, RNE, and RNE + RAD) (20.1–54.0 and 20.1–59.9 %, respectively) than in the NSR group (9.0 and 11.6 %, respectively) (P < 0.001). ST was independently associated with a decreased CSM (P < 0.0001). No significant differences in OS or the 1-, 3-, or 5-year DSS probabilities between the RNE and RNE + RAD groups were observed. RNE + RAD was not significantly associated with a decrease in 1-year CSM [subhazard ratio (SHR) 0.95; 95 % CI 0.23–3.96; P = 0.947].

Conclusions

Adjuvant external-beam radiation therapy did not increase OS in non-metastatic sRCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28(4):435–441

    Article  PubMed  Google Scholar 

  2. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167(1):65–70

    Article  PubMed  Google Scholar 

  3. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25(3):275–284

    Article  PubMed  Google Scholar 

  4. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A (1999) Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17(2):523–528

    CAS  PubMed  Google Scholar 

  5. Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, Chauvet B, Chevreau C, Eymard JC, Lesimple T, Merrouche Y, Oudard S, Priou F, Guillemare C, Gourgou S, Culine S, Genitourinary Group of the French Federation of Cancer C (2002) Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 168(3):959–961. doi:10.1097/01.ju.0000026902.77397.fd

    Article  CAS  PubMed  Google Scholar 

  6. Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: eCOG 8802. Med Oncol 29(2):761–767. doi:10.1007/s12032-011-9829-8

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG (2010) Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J medical Res 15:287–291

    Article  CAS  Google Scholar 

  8. Culine S, Bekradda M, Terrier-Lacombe MJ, Droz JP (1995) Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? Eur Urol 27(2):138–141

    CAS  PubMed  Google Scholar 

  9. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015) Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 13(2):e79–e85. doi:10.1016/j.clgc.2014.08.011

    Article  PubMed  Google Scholar 

  10. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA (2014) Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys 88(3):618–623. doi:10.1016/j.ijrobp.2013.11.207

    Article  PubMed  Google Scholar 

  11. Sano K, Kawasaki C, Sato K, Iwasaki A, Ishizuka E (1991) A case of renal cell carcinoma similar to rhabdoid tumor of kidney in an adult; trial of radiation and chemotherapy. Hinyokika Kiyo 37(12):1699–1702

    CAS  PubMed  Google Scholar 

  12. Harlan LC, Hankey BF (2003) The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 21(12):2232–2233. doi:10.1200/JCO.2003.94.023

    Article  PubMed  Google Scholar 

  13. American Joint Committee on Cancer (2010) AJCC cancer staging handbook from the AJCC cancer staging manual, 6th edn. Springer, New York

    Book  Google Scholar 

  14. Fine JP, Gray RJ (1999) A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 94(446):496–509. doi:10.1080/01621459.1999.10474144

    Article  Google Scholar 

  15. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, Kabbinaavar FF, Pantuck AJ, Belldegrun AS (2009) Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology–is up-front resection indicated and if not, is it avoidable? J Urol 182(5):2164–2171. doi:10.1016/j.juro.2009.07.049

    Article  PubMed Central  PubMed  Google Scholar 

  16. Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, Costello BA (2015) A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int 115(3):405–411. doi:10.1111/bju.12781

    Article  PubMed  Google Scholar 

  17. Aron M, Nguyen MM, Stein RJ, Gill IS (2008) Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 54(1):133–140. doi:10.1016/j.eururo.2007.12.001

    Article  PubMed  Google Scholar 

  18. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS (2012) Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 109(11):1600–1606. doi:10.1111/j.1464-410X.2011.10785.x

    Article  PubMed  Google Scholar 

  19. Delahunt B (1999) Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology 31(3):185–190

    Article  CAS  PubMed  Google Scholar 

  20. Bostrom AK, Moller C, Nilsson E, Elfving P, Axelson H, Johansson ME (2012) Sarcomatoid conversion of clear cell renal cell carcinoma in relation to epithelial-to-mesenchymal transition. Hum Pathol 43(5):708–719. doi:10.1016/j.humpath.2011.06.019

    Article  PubMed  Google Scholar 

  21. Conant JL, Peng Z, Evans MF, Naud S, Cooper K (2011) Sarcomatoid renal cell carcinoma is an example of epithelial–mesenchymal transition. J Clin Pathol 64(12):1088–1092. doi:10.1136/jclinpath-2011-200216

    Article  PubMed  Google Scholar 

  22. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005

    Article  PubMed  Google Scholar 

  23. Ulutin HC, Aksu G, Fayda M, Kuzhan O, Tahmaz L, Beyzadeoglu M (2006) The value of postoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori 92(3):202–206

    PubMed  Google Scholar 

  24. Stein M, Kuten A, Halpern J, Coachman NM, Cohen Y, Robinson E (1992) The value of postoperative irradiation in renal cell cancer. Radiother Oncol 24(1):41–44

    Article  CAS  PubMed  Google Scholar 

  25. Makarewicz R, Zarzycka M, Kulinska G, Windorbska W (1998) The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45(6):380–383

    CAS  PubMed  Google Scholar 

  26. Brookman-May S, Johannsen M, May M, Hoschke B, Gunschera J, Wieland WF, Burger M (2011) Difference between clinical and pathologic renal tumor size, correlation with survival, and implications for patient counseling regarding nephron-sparing surgery. AJR Am J Roentgenol 197(5):1137–1145. doi:10.2214/AJR.11.6534

    Article  PubMed  Google Scholar 

  27. Kurta JM, Thompson RH, Kundu S, Kaag M, Manion MT, Herr HW, Russo P (2009) Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int 103(1):24–27. doi:10.1111/j.1464-410X.2008.07941.x

    Article  PubMed Central  PubMed  Google Scholar 

  28. Herr HW, Lee CT, Sharma S, Hilton S (2001) Radiographic versus pathologic size of renal tumors: implications for partial nephrectomy. Urology 58(2):157–160

    Article  CAS  PubMed  Google Scholar 

  29. Irani J, Humbert M, Lecocq B, Pires C, Lefebvre O, Dore B (2001) Renal tumor size: comparison between computed tomography and surgical measurements. Eur Urol 39(3):300–303

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany

    Okyaz Eminaga, Ilgar Akbarov, Sebastian Wille & Udo Engelmann

Authors
  1. Okyaz Eminaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilgar Akbarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Wille
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Udo Engelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Okyaz Eminaga.

Ethics declarations

Conflicts of interest

The authors have no conflicts of interest, and this study received no financial or material support.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 222 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eminaga, O., Akbarov, I., Wille, S. et al. Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study. Int Urol Nephrol 47, 1653–1663 (2015). https://doi.org/10.1007/s11255-015-1093-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-1093-y

Keywords

Search

Navigation